REG - Plant Health Care - Approval of Harpinαβ in Belgium

Plant Health CareAnnouncement

22/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240422:nRSV3821La&default-theme=true

RNS Number : 3821L  Plant Health Care PLC  22 April 2024

22 April
2024

 

Plant Health Care plc

 ("Plant Health Care" or the "Company")

 

 Approval for Sale of Harpinαβ Granted in Belgium

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel
patent-protected biological products to global agriculture markets, is pleased
to announce that Harpinαβ, the Company's core, high-value fertilizer product
with biostimulant properties, has successfully achieved registration
in Belgium. This is a major operational milestone for the Company and permits
immediate sales of Harpinαβ in Belgium.

Following the initial regulatory approval in France in October 2022, Plant
Health Care has pursued approvals to expand the use of Harpinαβ
across Europe. Mutual recognition was achieved in Poland and Spain in 2023
and Portugal in February of 2024. With the granting of the derogation, Belgium
is the next EU country to authorize sales of Harpinαβ. Europe is the
world's largest market for sustainable agriculture with annual sales of
over $2 billion.

Harpinαβ is a recombinant protein that acts as a powerful biostimulant,
improving the yield and quality of crops. Plant Health Care is launching
Harpinαβ for use in European potato production, followed by fruit and
vegetable crops. Belgium is one of the leading agricultural producers in the
EU, and the Belgium potato harvest in 2023 was 4.85 million tons from 96,000
planted hectares.

 

The Company sells Harpinαβ through specialist distributors around the
world. Field trials are ongoing with interested distributors to observe the
results of Harpinαβ on treated potato plants and the Company plans to select
a distributor for the European market prior to the end of 2024.

 

Angel Marin, Director EMEAA for Plant Health Care, said: ‟It has been a
long-term goal of the Company to expand the use of its core
product, Harpinαβ across Europe's biggest agricultural markets. The
authorization to begin sales in Belgium brings us one-step closer and the
Company expects to select our distribution partner for the EU countries by
the end of the year. Harpinαβ is an environmentally friendly, and proven
protein technology which improves plant growth and development resulting in
higher quality, yields and long-term storage stability, which are critical as
the world seeks to address food security."

 

# # #

 

For further information, please contact:

 Plant Health Care plc
 Jeff Tweedy, CEO

                                                         Tel: +1 919 926 1600
 Cavendish Capital Markets Limited - Nomad & Broker      Tel: +44 (0) 131 220 9771
 Neil McDonald / Pete Lynch

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of
major field crops such as corn, soybeans, sugarcane, potatoes, rice, and
wheat, as well as specialty crops such as fruits and vegetables. We operate
globally through subsidiaries, distributors, and supply agreements with major
industry partners. Our innovative, patent-protected biological products help
growers to protect their crops from stress and diseases, and to produce higher
quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com (http://www.planthealthcare.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAGPUQCCUPCGWB